Publications
2021
Hong, NH. et al. Comprehensive preclinical characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor. 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. (Abstract: P192).
Read More > AACR-NCI-EORTC 2021 Poster Presentation. Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal inhibitor. 2021 AACR. (Abstract Number: 1209).
Read More > AACR 2021 Poster Presentation. Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer. ASCO GU 2021. (Abstract Number: 119).
Read More > ASCO-GU Poster Presentation
2020
. The preclinical characterization of the N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer. ENA 2020 – 32nd Symposium. (EORTC-NCI-AACR) (Abstract ID #181).
Read More > EORTC-NCI-AACR 32nd Symposium Poster. EPI-7386, a potent N-terminal domain androgen receptor inhibitor, with a favorable preclinical safety and superior in vitro/in vivo profile, in clinical development for prostate cancer. Prostate Cancer Foundation 27th Annual Scientific Retreat.
Read More > Prostate Cancer Foundation 27th Annual Scientific Retreat Poster